Drugs / CD33/CLL1 dual CAR-NK cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05987696 | Jul 2023 → Jan 2025 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06917105 | Apr 2025 → Apr 2027 expected | myeloid neoplasm | Tongji Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD33/CLL1 dual CAR-NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05987696 ↗ |
| Known as | CD33/CD123/CLL-1 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917105 ↗ |
| Modality | Cell therapy | “CD33/CLL1 dual CAR-NK cell” NCT05987696 ↗ |
| Target | CD33 | “CD33/CLL1 dual CAR-NK cell” NCT05987696 ↗ |